Stock BMYB34 BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Share Price Sao Paulo

Equities

BMYB34

BRBMYBBDR000

Pharmaceuticals

Market Closed - Sao Paulo
Other stock markets
 16:48:13 28/06/2024 BST 		5-day change 1st Jan Change
233 BRL +1.74% Intraday chart for Bristol-Myers Squibb Company +2.42% -6.77%
06-27 Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
06-26 2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT

Financials

Sales 2024 * 46.07B 258B 3,644B Sales 2025 * 46.06B 258B 3,643B Capitalization 84.19B 471B 6,659B
Net income 2024 * -5.41B -30.29B -428B Net income 2025 * 10.22B 57.18B 808B EV / Sales 2024 * 2.67 x
Net Debt 2024 * 39.04B 218B 3,088B Net Debt 2025 * 31.68B 177B 2,505B EV / Sales 2025 * 2.52 x
P/E ratio 2024 *
-15.8 x
P/E ratio 2025 *
7.86 x
Employees 34,100
Yield 2024 *
5.79%
Yield 2025 *
6.08%
Free-Float 69.27%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise MT
2seventy bio Sells Hemophilia A Candidate, Gene Editing Technology to Novo Nordisk; Shares Rise After Hours MT
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT
Bristol Myers: accelerated approval in colorectal cancer CF
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer CI
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval MT
US FDA approves Bristol Myers' colorectal cancer therapy RE
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo MT
Bristol Myers: application validated for subcutaneous Opdivo CF
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo CI
PTC Therapeutics, Inc. and Hopewell Campus Owner, LLC, as Successor-In-Interest to Bristol-Myers Squibb Company Enter into an Amendment and Restatement of the Lease of Office, Production and Laboratory Space At A Facility Located in Hopewell Township, New Jersey CI
Bristol Myers: ex-CEO of Agilent joins Board of Directors CF
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
More recommendations

Press releases Bristol-Myers Squibb Company

European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab AQ
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC) BU
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab BU
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024 BU
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : approbation accélérée en cancer colorectal
Bristol Myers : demande validée pour Opdivo sous-cutané
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil
Bristol Myers : dividendes décidés par le conseil
Bristol Myers : approbation de la FDA pour un traitement
More news

Quotes and Performance

1 day+1.74%
1 week+2.42%
Current month+10.95%
1 month+10.68%
3 months-10.82%
6 months-6.77%
Current year-6.77%
More quotes

Highs and lows

1 week
229.00
Extreme 229
234.50
1 month
210.00
Extreme 210
234.50
Current year
208.00
Extreme 208
270.81
1 year
208.00
Extreme 208
310.58
3 years
208.00
Extreme 208
431.76
5 years
160.29
Extreme 160.29
431.76
10 years
111.23
Extreme 111.23
431.76
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 31/01/15
David Elkins DFI
 Director of Finance/CFO 55 19/11/19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19/11/19
Peter Arduini BRD
 Director/Board Member 59 31/03/16
Derica Rice BRD
 Director/Board Member 59 31/08/20
More insiders

Quotes

Date Price Change Volume
28/06/24 233 +1.74% 2,011
27/06/24 229 -2.35% 2,071
26/06/24 234.5 +1.60% 880
25/06/24 230.8 +1.46% 3,300
21/06/24 227.5 +3.52% 12,647

Delayed Quote Sao Paulo, June 28, 2024 at 04:48 pm

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
04/07/2024 - Détachement de
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
41.53 USD
Average target price
53.19 USD
Spread / Average Target
+28.09%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.32% 815B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+44.05% 641B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.75% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+13.56% 314B
ABBVIE INC. Stock AbbVie Inc.
+10.68% 303B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.57% 242B
ROCHE HOLDING AG Stock Roche Holding AG
+2.04% 224B
NOVARTIS AG Stock Novartis AG
+13.31% 218B
AMGEN INC. Stock Amgen Inc.
+8.48% 168B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BMYB34 Stock